ESSA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.37 USD | +15.98% |
|
-6.12% | -18.64% |
| May. 20 | Top Premarket Decliners | MT |
| May. 14 | ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 327M 238M |
|---|---|---|---|---|---|
| Net income 2024 * | -48M -34.92M | Net income 2025 * | -72M -52.38M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.6
x | P/E ratio 2025 * |
-5.29
x | Employees | 50 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on ESSA Pharma Inc.
More recommendations
More press releases
| 1 day | +15.98% | ||
| 1 week | -6.12% | ||
| Current month | -20.44% | ||
| 1 month | -10.50% | ||
| 3 months | -39.66% | ||
| 6 months | -10.50% | ||
| Current year | -18.64% |
1 week
4.59
5.83
1 month
4.596.85
Current year
4.5911.67
1 year
2.5811.67
3 years
1.4030.26
5 years
1.4036.00
10 years
1.40245.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 15-06-23 |
David Wood
DFI | Director of Finance/CFO | 66 | 13-09-30 |
Peter Virsik
COO | Chief Operating Officer | - | 16-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 15-03-04 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 19-07-30 |
Richard Glickman
CHM | Chairman | 65 | 10-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 5.37 | +15.98% | 65,096 |
| 24-06-13 | 4.63 | -10.96% | 171,329 |
| 24-06-12 | 5.2 | -4.94% | 64,922 |
| 24-06-11 | 5.47 | +0.74% | 42,305 |
| 24-06-10 | 5.43 | -5.07% | 113,328 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotes
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
2024-08-12
- Q3 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.382
CAD
Average target price
26.67
CAD
Spread / Average Target
+261.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.64% | 238M | |
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
- Stock Market
- Equities
- EPIX Stock
